Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancer

Trastuzumab Deruxtecan for HER2-Low Metastatic Breast Cancer | Dr. Jitendra PahlajaniПодробнее

Trastuzumab Deruxtecan in HER2-Low Advanced Breast Cancer | NEJMПодробнее

TALENT: neoadjuvant T-DXd with or without anastrozole for HER2-low, HR+ early stage breast cancerПодробнее

HER2-low mBC patients report preserved QOL with trastuzumab deruxtecanПодробнее

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast CancerПодробнее

Antibody-Drug Conjugates into the Management of HR+ and Triple-Negative Metastatic Breast CancerПодробнее

Metastatic Breast Cancer | 2022 OneOncology ConferenceПодробнее

Smilow Shares: Breast Cancer Education Series (CME) - Treatment Advances/Clinical TrialsПодробнее

Dr. Hamilton on the Efficacy of Trastuzumab Deruxtecan in HER2-Low Breast CancerПодробнее

HER2 In Breast Cancer: Testing Guidelines and New Treatment ApproachesПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Reshma MahtaniПодробнее

ASCO 2022: Trastuzumab deruxtecan vs. treatment of physician's choice in HER2-low unresectable a...Подробнее

Medical update: HER2-Positive and triple-positive metastatic breast cancerПодробнее

Trastuzumab deruxtecan doubles PFS in metastatic breast cancer with low HER2 expressionПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvementПодробнее